On this page
Where do nonclinical drug interaction reports belong in the CTD?
Nonclinical pharmacodynamic interaction reports belong under 4.2.1.4; pharmacokinetic interaction reports belong under 4.2.2.6 in the FDA hierarchy. Determine whether the experiment addresses response, disposition or both. Describe the tested direction of interaction and avoid converting an experimental result into an unsupported clinical dosing recommendation.
Before you begin
Nonclinical interaction reports in 4.2.1.4 and 4.2.2.6. Human interaction studies belong in the appropriate Module 5 context.
What you will prepare: An interaction report that identifies the comparison, attributes the measured effect carefully and resolves its main placement.
Sections covered in this guide (2)
Write down what “interaction” means in this experiment
A pharmacodynamic interaction concerns the response when agents are considered together. A pharmacokinetic interaction concerns absorption, distribution, metabolism or elimination and the resulting exposure. The FDA hierarchy provides separate nonclinical locations for these tasks. Do not choose a location from the abbreviation “DDI” alone.
Record the study objective, both agents or relevant metabolites, the test system and the primary comparisons. If the work measures both response and concentration, describe both and agree the primary location with the dossier owners. A clinical interaction report is not nonclinical evidence merely because it includes an in vitro appendix.
Recover the exact comparison behind the claim
Obtain the treatment or incubation scheme, individual-agent conditions, combination conditions, controls, administration sequence, measured concentrations, response outputs and analysis method. Make the relationship between nominal concentration and measured exposure explicit. Record whether the experiment used parent compound, a metabolite or a mixture.
For response comparisons, show the observed combination result alongside the individual-agent results and the analytical framework actually used. Do not use “synergy” as a synonym for a larger response; obtain the scientist's model and criterion. For disposition work, distinguish a measured change from a predicted clinical implication, and identify limitations such as test-system relevance, concentration range and assay interference.
Describe results without inventing clinical magnitude
A clear report moves from objective and methods to the relevant comparisons, uncertainties and a bounded conclusion. State which direction of interaction was evaluated: the effect of agent A on agent B is not automatically evidence for the reverse direction. Explain unsuccessful or uninterpretable comparisons as well as interpretable results.
A decision to perform additional combination safety work depends on the clinical context and existing evidence. M3(R2) and FDA's product-specific resources provide development context; neither the existence of a CTD interaction heading nor this writing outline establishes that a new study is necessary. Keep a request for new evidence separate from the report of evidence already generated.
Challenge a stronger-response explanation
Fictional example: the combination arm has a greater biological response than agent A alone, and the draft calls this a pharmacodynamic synergy. The companion concentration results also suggest a change in agent A exposure. The reviewer should ask whether the design and analysis distinguish altered exposure from the claimed response mechanism.
Retain both observations, identify the unresolved explanation and qualify the conclusion. If no concentration evidence exists, report that limitation rather than declaring that exposure was unchanged. Link the interaction conclusion to the appropriate Module 2 summary with the same qualifications.
Make the comparison and direction of interaction explicit
Use one row per actual comparison. A single “DDI result” field can conceal which agent was affected and whether the observed difference concerns exposure or response.
| Comparison | Record alongside the result | Question for the study author |
|---|---|---|
| A alone versus A with B | Matched A dose or concentration and measured endpoint | What changed when B was present? |
| B alone versus B with A | Matched B conditions, if this comparison was conducted | Was the reverse direction actually evaluated? |
| Combination response | Individual-agent responses and analysis framework | Does the analysis support the proposed interaction term? |
| Combination exposure | Analyte identity, sampling and analytical method | Could an exposure difference explain the response? |
Mark a comparison “not studied” when it was absent. Do not copy the result from the opposite direction. Where designs or sampling differ, explain why a direct comparison is or is not interpretable before presenting a ratio or combined conclusion.
Handoff example: agent A exposure changes in the presence of B, but no B concentration measurements were collected. A useful report states the observed effect on A and the missing reverse-direction evidence. It does not describe “no bidirectional interaction.” If the response also changed, the scientist should explain what the experiment can distinguish about cause.
Send the qualified disposition finding to the PK summaries and the response finding to the pharmacology summaries, with a common study identifier. These complementary accounts should not turn one uncertain explanation into two apparently confirmed mechanisms.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is a greater combination response proof of synergy?
No. A greater response alone does not identify the underlying interaction or establish synergy. The report needs the actual individual-agent comparisons and the scientific analysis supporting that term. Changes in exposure or other design factors may also affect the interpretation.
Can a nonclinical interaction study determine a clinical dose adjustment?
The experimental result can inform further interpretation, but a clinical dose recommendation requires an appropriate bridge to the human context and supporting evidence. Keep the observed nonclinical effect, any prediction and the clinical decision distinct rather than reporting them as one measured outcome.
Does the existence of an interaction heading require a new study?
No. A CTD heading provides a location for evidence, not a universal instruction to generate it. The need for additional combination or interaction work depends on the product, clinical context and existing evidence assessed under the applicable development strategy.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Technical specification
FDA eCTD v4.0 headings and hierarchy ↗Version 2.2, February 2025; Module 4, printed pages 6–10. Technical placement and allowable document types, not a required-study list. Checked September 22, 2026.
Guidance
ICH M3(R2): nonclinical safety studies ↗Step 4, June 11, 2009; sections 1–5, 8–17. Development context and timing, not an automatic requirement for each heading. Checked September 22, 2026.
FDA resource
FDA streamlined nonclinical studies and NAMs ↗Live CDER resource checked September 22, 2026. Product-specific recommendations and links include draft guidance; inspect the applicable linked document before making a study-plan decision.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 4.2.1.4. A heading identifies placement, not mandatory applicability.